花旗发表研究报告指,中生制药(01177.HK) 旗下正大天晴与德国药企STADA就生物类似药达成战略合作,授予STADA在欧盟、瑞士、英国及独立国家联合体商业化帕博利珠单抗生物类似药(TQB3570,抗PD-1单克隆抗体)的独家许可,并可选择拓展至美国及海湾合作委员会成员国(GCC)市场。花旗认为合作带来惊喜。根据协议,正大天晴将收取首付款及高达5,300万欧元的开发、监管及销售里程碑付款,并...
Source Link花旗发表研究报告指,中生制药(01177.HK) 旗下正大天晴与德国药企STADA就生物类似药达成战略合作,授予STADA在欧盟、瑞士、英国及独立国家联合体商业化帕博利珠单抗生物类似药(TQB3570,抗PD-1单克隆抗体)的独家许可,并可选择拓展至美国及海湾合作委员会成员国(GCC)市场。花旗认为合作带来惊喜。根据协议,正大天晴将收取首付款及高达5,300万欧元的开发、监管及销售里程碑付款,并...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.